Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | TLR2 | O60603 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064352 | 1.00 | MDM4 (0.49) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL29462653 | 0.92 | MDM2 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL524544 | 0.92 | MDM2 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL30670316 | 0.92 | MDM2 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL621563 | 0.92 | MDM2 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL29462655 | 0.92 | MDM2 (0.56) | MDM4TP53CASP3MDM2TLR2 | |
| SCHEMBL27401805 | 0.90 | KMT2A (0.51) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL8138543 | 0.90 | KMT2A (0.51) | MDM4TP53CASP3KMT2ATLR2 | |
| SCHEMBL377523 | 0.89 | MDM4 (0.50) | MDM4TP53CASP3KMT2AMDM2 | |
| SCHEMBL1784562 | 0.89 | TLR2 (0.50) | MDM4TP53CASP3KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2274297-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
| WO-2009127546-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | MDM4 4738/4885TP53 4199/4885CASP3 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.